Welcome to our dedicated page for Entrada Therapeutics SEC filings (Ticker: TRDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Entrada Therapeutics filings document a clinical-stage biopharmaceutical issuer developing genetic medicines that engage intracellular targets. Recent Form 8-K reports furnish quarterly and annual financial results, cash and marketable-securities updates, and corporate updates related to its Duchenne muscular dystrophy franchise, ocular disease pipeline and partnered VX-670 program for myotonic dystrophy type 1.
Proxy materials describe annual meeting matters, including director elections, auditor ratification and amendments to the company’s stock option and employee stock purchase plans. The filings also identify TRDA common stock listed on The Nasdaq Global Market, emerging growth company status, Regulation FD disclosures and governance matters tied to equity compensation and stockholder voting.
Kory Wentworth reported planned sales of Common Stock under a 10b5-1 plan. The filing lists three trades: 03/02/2026 sale of 2,939 shares for $34,262.57, 03/03/2026 sale of 5,712 shares for $67,152.56, and 03/04/2026 sale of 7,988 shares for $97,892.14. The broker listed is Morgan Stanley Smith Barney LLC. The filing also records securities listed as previously exercised stock options (9,395 shares, 06/29/2023) and restricted stock units (7,082 shares, 09/01/2025).
Nathan Dowden reported two sales of Common stock: 7,223 shares on 03/02/2026 for $84,205.01 and 14,038 shares on 03/03/2026 for $165,036.34. The filing also lists 15,010 Restricted Stock Units dated 03/01/2024 and a securities line showing 38,284,313 (03/09/2026).
Entrada Therapeutics Chief Financial Officer Kory James Wentworth sold 7,988 shares of common stock in an open-market transaction. The sale occurred on March 4, 2026 at a weighted average price of $12.2549 per share, with individual trade prices ranging from $11.80 to $12.57.
The transaction was carried out under a pre-arranged Rule 10b5-1 trading plan adopted by the executive on March 6, 2025. Following this sale, Wentworth directly holds 137,987 shares of Entrada Therapeutics common stock.
Morgan Stanley Smith Barney LLC Executive Financial Services submitted a Form 144 relating to TRDA securities, showing 7,988 restricted stock units listed to be sold by the broker/issuer role on 03/01/2026. The filing also reports recent dispositions by Kory Wentworth of 5,712 and 2,939 common shares on 03/03/2026 and 03/02/2026, respectively, with reported proceeds of $67,152.56 and $34,262.57.
Entrada Therapeutics CEO Dipal Doshi reported new equity awards and automatic tax-related share sales. On March 1, 2026, Doshi received 139,400 restricted stock units under the 2021 Stock Option and Incentive Plan and a stock option covering 208,000 shares of common stock, both granted at $0.00 per share.
The RSUs vest in four 25% installments each March 1 from 2027 through 2030, while 25% of the option vests on March 1, 2027 and the rest monthly through March 1, 2030. On March 2 and 3, 2026, a total of 29,050 shares of common stock were automatically sold by the company under a mandatory sell-to-cover provision to satisfy minimum tax withholding, at weighted average prices of $11.6579 and $11.7564 per share.
Following these transactions, Doshi directly owned 526,014 shares of Entrada Therapeutics common stock.
Entrada Therapeutics Chief Financial Officer Kory James Wentworth reported equity compensation grants and related tax-withholding share dispositions. On March 1, 2026, he received 66,600 stock options and 44,600 restricted stock units under the 2021 Stock Option and Incentive Plan, both vesting in stages through March 1, 2030.
The filing also shows mandatory sell-to-cover transactions where the company automatically sold 5,712 shares at a weighted average price of $11.7564 on March 3, 2026 and 2,939 shares at $11.6579 on March 2, 2026 to cover minimum statutory tax withholding obligations, not discretionary trades by Wentworth. After these transactions, he directly owned 145,975 common shares and 66,600 options.
Entrada Therapeutics President & COO Nathan J. Dowden reported equity compensation grants and related tax-withholding share dispositions. On March 1, 2026, he received 55,800 shares of common stock as restricted stock units and a stock option for 83,200 shares, both granted at $0.00 per share.
The RSUs vest in four equal 25% installments each March 1 from 2027 through 2030, while the option vests 25% on March 1, 2027 and the remaining 75% in 36 monthly installments through March 1, 2030. On March 2 and March 3, 2026, a total of 21,261 shares of common stock were automatically disposed of at weighted average prices of $11.6579 and $11.7564 to satisfy minimum statutory tax withholding obligations under a mandatory sell-to-cover provision, and did not represent discretionary trades. After these transactions, Dowden directly held 213,598 shares of common stock and 83,200 option shares.
Entrada Therapeutics, Inc. reported that President of Research & Development Sethuraman Natarajan received new equity awards and had shares disposed to cover tax obligations. On March 1, 2026, he was granted 55,800 restricted stock units (RSUs), each representing one share of common stock, scheduled to vest 25% each on March 1, 2027, March 1, 2028, March 1, 2029, and March 1, 2030, contingent on continued service. He also received a stock option for 83,200 shares of common stock, with 25% vesting on March 1, 2027 and the remaining 75% vesting in 36 equal monthly installments through March 1, 2030. To satisfy minimum statutory tax withholding obligations, the company automatically sold shares on his behalf: 3,898 shares of common stock on March 2, 2026 at a weighted average price of $11.6579 (across trades from $11.17 to $11.91) and 7,577 shares on March 3, 2026 at a weighted average price of $11.7564 (across trades from $11.22 to $12.095). After these transactions, he directly owned 242,224 shares of Entrada’s common stock.
Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing intracellular genetic medicines, led by exon-skipping therapies for Duchenne muscular dystrophy (DMD) and a partnered program for myotonic dystrophy type 1 (DM1) with Vertex.
In 2026, the company plans data readouts from multiple DMD trials, including ENTR‑601‑44 and ENTR‑601‑45, and regulatory progress for ENTR‑601‑50 and ENTR‑601‑51. Vertex’s VX‑670 DM1 trial is expected to complete enrollment and dosing in mid‑2026. Entrada is also advancing ENTR‑801 for Usher syndrome type 2A and a broader ocular and preclinical pipeline based on its Endosomal Escape Vehicle (EEV) platform.
Entrada Therapeutics reported fourth-quarter and full-year 2025 results that reflect a shift from collaboration-driven revenue to heavier investment in its genetic medicines pipeline. Collaboration revenue fell to $1.3 million in the fourth quarter and $25.4 million for 2025, down from $37.4 million and $210.8 million in 2024, mainly because work under the VX-670 collaboration research plan substantially finished in early 2025.
Research and development spending rose to $142.3 million for 2025, helping drive a full-year net loss of $143.8 million after net income of $65.6 million in 2024. The company ended 2025 with $295.7 million in cash, cash equivalents and marketable securities and expects this to fund operations into the third quarter of 2027. Entrada highlighted progress across multiple Duchenne muscular dystrophy programs, including a positive independent committee recommendation to escalate dosing in the ELEVATE-44-201 study, and outlined clinical data readouts expected throughout 2026.